Insulin-like growth factor-1 receptor crosstalk with integrins, cadherins, and the tumor microenvironment: sticking points in understanding IGF1R function in cancer.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanistic biology and clinical trial observations without formal systematic review or primary data analysis.
PubMed 37490874 · doi:10.1530/ERC-23-0031
What was done
The authors conducted a narrative review examining why insulin-like growth factor-1 receptor (IGF1R) inhibitors failed in clinical trials. They evaluated published clinical trial reports and mechanistic literature regarding IGF1R crosstalk with cell adhesion molecules (integrins, cadherins) and its functional roles in tumor-associated immune and stromal cells.
What was found
The abstract reports no numerical findings or quantitative metrics. Qualitatively, it highlights that IGF1R exhibits context-dependent, tumor-suppressive activities, including the promotion of E-cadherin-mediated cell-cell adhesion, induction of a pro-inflammatory macrophage phenotype, and stimulation of immunoglobulin production in B cells, which may be disrupted by non-selective inhibition.
Why it matters
Identifying the multi-faceted and potentially protective functions of IGF1R in cell adhesion and tumor immunity provides a mechanistic explanation for past clinical trial failures and offers biological rationale for future biomarker-driven patient stratification.
Limits
As a narrative review, it lacks a systematic search protocol, risk-of-bias evaluation, or pooled statistical analysis. The abstract does not report specific trial counts, patient sample sizes, or quantitative outcome measures.
Cited by
- supports Multiple clinical trials evaluating IGF-1 pathway inhibitors as cancer therapies failed.